Clinical Report: FDA approves oral dermatomyositis therapy
Overview
The FDA has approved brepocitinib (Lisraya) as the first oral treatment for dermatomyositis. This approval follows a phase 3 trial demonstrating improved Total Improvement Scores in patients receiving brepocitinib compared to placebo.
Background
Dermatomyositis is a rare autoimmune disease characterized by muscle weakness and skin rashes, leading to significant morbidity.
Data Highlights
| Study Design | Participants | Results |
|---|---|---|
| Phase 3, randomized, double-blind, placebo-controlled | 241 adults | Brepocitinib 30 mg showed higher Total Improvement Scores at week 52 compared to placebo. |
Key Findings
- Brepocitinib is the first FDA-approved oral therapy for dermatomyositis.
- The phase 3 trial involved 241 adults and assessed Total Improvement Scores over 52 weeks.
- Participants receiving brepocitinib 30 mg experienced greater improvements in physical function and skin disease activity.
- Adverse reactions included upper respiratory tract infections and headaches, with 6% discontinuation in the 30 mg group.
- Brepocitinib carries warnings for serious infections and increased all-cause mortality.
Clinical Implications
Healthcare providers should consider brepocitinib as a treatment option for adults with dermatomyositis, particularly for those who have not responded to other therapies. Monitoring for adverse effects, especially serious infections, is essential during treatment.
Conclusion
The approval of brepocitinib represents a significant advancement in the management of dermatomyositis, offering a new oral treatment option for affected patients.
Related Resources & Content
- US Food and Drug Administration, FDA, 2026 -- FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
- MDSpire News, Targeted therapy tested in dermatomyositis, 2026 -- Targeted therapy tested in dermatomyositis
- MDSpire News — FDA Approves New Oral Option for Plaque Psoriasis
- MDSpire News — Novel Therapies May Represent the Future of Treating Cutaneous Autoimmune Diseases
- reuters — FDA Approves New Drug for Rosacea
- FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults | FDA
- Idiopathic inflammatory myopathies - Symptoms, diagnosis and treatment | BMJ Best Practice US
- Frontiers | Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis/dermatomyositis: a single-arm systemic meta-analysis
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
